GLP-1 news, dated and sourced
New approvals, new prices and new rules, newest first. Each line quotes FDA, CMS, the White House or the maker.
Sources read Sep 27, 2026.
TrumpRx passes $700 million in savings
- The White House says TrumpRx has delivered more than $700 million in savings and now covers more than 1,000 branded and generic medicines.
The platform has delivered more than $700 million in savings and now covers more than 1,000 branded and generic medicines.
whitehouse.gov, Sep 30, 2026
- The White House says TrumpRx has delivered more than $700 million in savings and now covers more than 1,000 branded and generic medicines.
Two different counts of seniors on $50 GLP-1s
The White House has given two numbers for the same $216 million. None of these sentences names the Medicare GLP-1 Bridge, and CMS has published no count.
- August 31 fact sheet: over 500,000 seniors saved $216 million in the two months since $50 access began in July 2026.
In July of 2026, senior citizens without access to GLP-1 coverage to treat obesity gained access for just $50 per month. In the two months since the launch of this program, over 500,000 seniors have saved a total of $216 million dollars on these life-changing medicines.
whitehouse.gov, Sep 30, 2026 - September 18 fact sheet: 600,000 seniors, the same $216 million.
In the two months since the launch of this program, 600,000 seniors have saved a total of $216 million dollars on these life-changing medicines.
whitehouse.gov, Sep 30, 2026 - September 18 release: more than 500,000 seniors, the same $216 million.
GLP-1 drugs that once cost over $1,000 a month start as low as $149; eligible Medicare seniors pay just $50 a month, with more than 500,000 seniors already saving $216 million.
whitehouse.gov, Sep 30, 2026
- August 31 fact sheet: over 500,000 seniors saved $216 million in the two months since $50 access began in July 2026.
Mounjaro: a new indication
- FDA's drug database lists a new Mounjaro indication approved August 27, 2026, without naming it.
08/27/2026 SUPPL-44 Efficacy-New Indication
accessdata.fda.gov, Sep 30, 2026 - Lilly's Mounjaro site says it is now also approved to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes at high risk.
It's now also approved to lower the risk of heart attack, stroke, or cardiovascular death for adults with type 2 diabetes at high risk for these events.
mounjaro.lilly.com, Sep 27, 2026
- FDA's drug database lists a new Mounjaro indication approved August 27, 2026, without naming it.
Saxenda is being discontinued
- Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027.
Novo Nordisk is providing advance notice that we will be discontinuing Saxenda®, with last shipments to wholesalers taking place in late January 2027.
novocare.com, Sep 30, 2026 - Novo Nordisk says the decision is not due to safety or quality concerns.
As alternative medicines have become available and the number of patients using Saxenda® has continued to decline, Novo Nordisk has made the strategic portfolio decision to discontinue the brand. This decision is not the result of any safety or quality-related concerns.
novocare.com, Sep 30, 2026 - FDA's shortage database lists it as a discontinuation, available until January 2027.
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) 08/25/2026 Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
accessdata.fda.gov, Sep 30, 2026
- Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027.
How the Medicare GLP-1 Bridge is run
- Makers supply Bridge drugs at a net price of $245 per monthly supply.
Under the Medicare GLP-1 Bridge, participating manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply.
cms.gov, Sep 30, 2026 - CMS uses Humana as the Bridge's central processor.
CMS will be utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge.
cms.gov, Sep 30, 2026
- Makers supply Bridge drugs at a net price of $245 per monthly supply.
Medicare GLP-1 Bridge starts
- Eligible Medicare beneficiaries can get certain GLP-1s for $50 a month.
Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program.
cms.gov, Sep 30, 2026 - CMS announced on May 6, 2026 that the $50 price runs from July 1, 2026 through December 31, 2027.
The Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027.
cms.gov, Sep 30, 2026
- Eligible Medicare beneficiaries can get certain GLP-1s for $50 a month.
FDA proposes keeping GLP-1s off the bulk compounding list
- FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list of bulk drugs outsourcing facilities may compound from.
The U.S. Food and Drug Administration today announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
fda.gov, Sep 30, 2026
- FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list of bulk drugs outsourcing facilities may compound from.
Foundayo approved
- FDA approved Foundayo (orforglipron).
The U.S. Food and Drug Administration today approved Foundayo (orforglipron), marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.
fda.gov, Sep 30, 2026 - It is approved for adults with obesity, or overweight with at least one weight-related condition.
Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
fda.gov, Sep 30, 2026
- FDA approved Foundayo (orforglipron).
Wegovy 7.2 mg approved
- FDA approved a higher 7.2 mg dose of Wegovy injection.
The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, called Wegovy HD, for weight loss and long-term maintenance of weight loss for certain adult patients.
fda.gov, Sep 30, 2026 - It is for adults with obesity, or overweight with at least one weight-related condition.
The new higher dose of Wegovy is indicated to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition.
fda.gov, Sep 30, 2026
- FDA approved a higher 7.2 mg dose of Wegovy injection.
FDA warns 30 telehealth companies
- FDA sent 30 warning letters over false or misleading claims about compounded GLP-1s.
The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
fda.gov, Sep 30, 2026
- FDA sent 30 warning letters over false or misleading claims about compounded GLP-1s.
TrumpRx.gov launches
- The White House announced TrumpRx.gov.
HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced the launch of TrumpRx.gov.
whitehouse.gov, Sep 30, 2026 - You need a valid prescription; savings come as coupons or through the maker's own channel.
Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov.
whitehouse.gov, Sep 30, 2026 - Announced prices: Ozempic and Wegovy injection from $1,028 and $1,349 down to an average of $350, as low as $199.
The monthly prices of Ozempic® and injectable Wegovy® drop from $1,028 and $1,349, respectively, to an average of $350 and as low as $199, depending on dosage.
whitehouse.gov, Sep 30, 2026 - The Wegovy pill as low as $149.
The monthly price of the Wegovy® pill falls from $1,349 to as low as $149, depending on dosage.
whitehouse.gov, Sep 30, 2026 - Zepbound an average of $346, as low as $299.
The monthly price of Zepbound® falls from $1,088 to an average of $346 and as low as $299, depending on dosage.
whitehouse.gov, Sep 30, 2026
- The White House announced TrumpRx.gov.
Wegovy pill approved
- Novo Nordisk says FDA approved the Wegovy pill (oral semaglutide 25 mg) for weight management and to lower the risk of major heart events.
Bagsværd, Denmark, 22 December 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.
novonordisk.com, Sep 30, 2026 - Novo Nordisk calls it the first oral GLP-1 approved for weight management.
The Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.
novonordisk.com, Sep 30, 2026
- Novo Nordisk says FDA approved the Wegovy pill (oral semaglutide 25 mg) for weight management and to lower the risk of major heart events.
Counterfeit Ozempic seized
- FDA seized counterfeit Ozempic 1 mg found in the legitimate U.S. supply chain.
[12/5/2025] FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were distributed illegally outside of Novo Nordisk's authorized supply chain. The seized counterfeit products were in the legitimate U.S. drug supply chain.
fda.gov, Sep 30, 2026
- FDA seized counterfeit Ozempic 1 mg found in the legitimate U.S. supply chain.
FDA “green list” for GLP-1 ingredients
- FDA started an import alert to stop GLP-1 ingredients from unverified foreign sources.
The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.
fda.gov, Sep 30, 2026
- FDA started an import alert to stop GLP-1 ingredients from unverified foreign sources.
Wegovy approved for MASH
- Novo Nordisk says FDA approved Wegovy for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) in adults.
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.
novonordisk.com, Sep 30, 2026 - It is an accelerated approval.
The accelerated approval is based on part 1 of the ESSENCE trial
novonordisk.com, Sep 30, 2026
- Novo Nordisk says FDA approved Wegovy for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) in adults.
Semaglutide shortage resolved
- FDA declared the semaglutide injection shortage resolved.
[2/21/2025] FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand.
fda.gov, Sep 30, 2026
- FDA declared the semaglutide injection shortage resolved.
Zepbound approved for sleep apnea
- FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.
Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.
fda.gov, Sep 30, 2026
- FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.